Introduction-Diadenosine 5',5"'-P 1 ,P 4 -tetraphosphate (Ap 4 A) is stored in platelet dense granules, but its effects on platelet function are not well understood.
Introduction
Platelets express three purinergic receptors, P2X 1 , P2Y 1 and P2Y 12 (Fig. 1) . [1, 2] P2X 1 receptors are activated by adenosine 5'-triphosphate (ATP) while P2Y 1 and P2Y 12 receptors are both activated by adenosine 5'-diphosphate (ADP) [1, 2] . The P2X 1 receptor is a ligandgated ion channel which upon activation triggers fast influx of extracellular Ca 2+ into the cytoplasm and transient platelet shape change (Fig. 1 ) [1] [2] [3] [4] . P2Y 1 and P2Y 12 are G-protein coupled receptors, P2Y 1 being coupled to G q and P2Y 12 to G i [1, 2] . Upon activation, P2Y 1 triggers Ca 2+ mobilization from the platelet dense tubular system, shape change, and reversible platelet aggregation (Fig. 1 ) [1, 2] . Activation of P2Y 12 leads to inhibition of the adenylyl cyclase-dependent production of cytoplasmic cyclic adenosine 5'-monophosphate (cAMP) and propagation of stable platelet aggregation [1, 2] . cAMP activates protein kinase A which then phosphorylates vasodilator stimulated protein (VASP) [2, 5] , a modulator of platelet cytosolic proteins ( Fig. 1 ). Both P2Y 1 and P2Y 12 play major roles in the amplification and stabilization of platelet activation. The exact physiological role of P2X 1 is less clear, but it plays a role in the enhancement of the effect of low levels of primary platelet activators and in high shear stress activation [1, 2] . Diadenosine 5',5"'-P 1 ,P 4 -tetraphosphate (Ap 4 A) and other diadenosine polyphosphates are naturally occurring compounds that are ubiquitous in mammalian tissues [6] , including human platelets [7, 8] . They may serve as neurotransmitters [9] and modulators of vascular tone [10] .There is growing evidence that Ap 4 A plays a role in systemic diseases such as diabetes mellitus and hypertension [11, 12] . In platelets, Ap 4 A is stored in dense granules, and is therefore released along with ADP and ATP upon platelet activation [8, 13] . Ap 4 A and its analogs are known to inhibit ADP-induced platelet activation [14, 15] . Ap 4 A analogs inhibit the ADP-induced platelet release reaction, calcium mobilization, thromboxane production and platelet factor 3 activities [14] . However, these studies [14, 15] were performed before all three platelet purinergic receptors were cloned and their functions characterized. Therefore, the mechanism by which Ap 4 A inhibits ADP-induced platelet activation and its possible effects on P2Y 1 and P2Y 12 are unknown. Diadenosine polyphosphates are potent agonists of P2X receptors expressed on a variety of human and rat cell types [16, 17] . Although human platelets express P2X 1 receptors [18] [19] [20] , whether Ap 4 A is an agonist via platelet P2X 1 is unknown. The goal of the present study was, therefore, to elucidate the effects of Ap 4 A on signaling through P2Y 1 , P2Y 12 and P2X 1 receptors on human platelets. We demonstrate that Ap 4 A, a known constituent of platelet dense granules, is: a) an antagonist of platelet P2Y 1 and P2Y 12 receptors, where it inhibits the effects of the agonist ADP, b) an agonist of P2X 1 receptors, and c) a partial agonist of P2Y 12 receptors.
Materials and Methods

Chemicals and reagents
Ap 4 A was synthesized by a novel method (to be published) and was >98% pure by reverse phase HPLC. MRS2179, MRS2159, probenecid, adenosine 5'-(β,γ-methylene)triphosphate (β,γ-CH 2 -ATP) and apyrase (grade VII) were purchased from Sigma-Aldrich (St. Louis, MO). D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) was purchased from Calbiochem (EMD Biosciences, La Jolla, CA). FLUO-4 was from Invitrogen (Carlsbad, CA),ADP was from Bio/Data (Horsham, PA), CD41-phycoerythrin (PE)-Cy5 was from Beckman Coulter (Fullerton, CA), and AR-C69931 was from AstraZeneca (Charnwood, UK).
Blood collection and sample preparation
Human blood samples were taken from healthy volunteer donors who had been free from aspirin or other non-steroidal anti-inflammatory drugs for more than 7 days. IRB-approved written informed consent was obtained before blood collection. Unless otherwise specified, blood was drawn from antecubital veins into 3.2% sodium citrate tubes. Whole blood was used in VASP phosphorylation and P2Y 1 cytosolic Ca 2+ assays. For platelet aggregation tests, the blood was centrifuged at 110 g for 12 minutes and platelet-rich plasma (PRP) was immediately removed. The remaining samples were further centrifuged at 1650 g for 10 minutes to obtain platelet-poor plasma (PPP), which was used as a reference. For assays of platelet P2X 1 receptor functions, whole blood was drawn into tubes containing PPACK (0.3 mM, final concentration) and apyrase (1.8 µM final concentration). The samples were then centrifuged and processed to retrieve PRP and PPP.
ADP-induced platelet aggregation and shape change
Light transmission platelet aggregation was performed as previously described [21] . ADP (3 µM) in the presence or absence of various concentrations of Ap 4 A was added to PRP, and the aggregation response was recorded for a total of six minutes in a Chrono-log® aggregometer running the Aggro/Link software (Chrono-log®, Havertown, PA).
For observation of ADP-induced platelet shape change, EDTA (final concentration 10 mM) was mixed with PRP to allow ADP-induced shape change but to avoid platelet-platelet aggregation. After obtaining a stable baseline tracing in the aggregometer ADP (3 µM), in the presence or absence of various concentrations of Ap 4 A, was added to induce platelet shape change, and the tracing recorded for a total of 4 minutes.
Platelet aggregation measured by microplate reader
The 96-well microplate method for the detection of platelet aggregation is a simple, rapid, low volume method to simultaneously measure platelet aggregation of multiple samples, thereby avoiding the variable of platelet aging [22, 23] . In brief, ADP (5 µL, final concentration 3 µM) and Ap 4 A (5 µL, at various concentrations) were added to each well of a flat bottom 96-well Immulon microplate (Thermo Fisher Scientific, Waltham, MA). PRP (90 µL) was then added to each well with a multi-channel pipette, and light transmission was recorded with a Molecular Devices microplate reader, running SOFTmax Pro 4.0 software at 580 nm wavelength under the kinetic mode, with intermittent shaking and readings every 11 seconds at 37°C. Results of platelet aggregation measured by the microplate method have been demonstrated to be comparable to results of conventional platelet aggregation [22, 23] . Similarly, we observed comparable Ap 4 A inhibition of ADP-stimulated platelet aggregation by these two methods in the present study (Figure 2A and 2B ). Since the microplate method avoids possible aging artifacts, results from this method were used to calculate the IC 50 for Ap 4 A.
P2Y 12 -mediated VASP phosphorylation assay
VASP phosphorylation (Fig. 1) was measured by flow cytometry [5] using a kit (BioCytex, Marseilles, France) essentially according to the manufacturer's recommendations. In brief, Ap 4 A or vehicle (2 µL) was added to each set of assay tubes, followed by prostaglandin E 1 (PGE 1 , 9 µL) or the same volume of PGE1 plus ADP. Citrated whole blood (10 µL) was then added to each tube, and the samples were incubated for 10 minutes at room temperature. The samples were then fixed, permeabilized, and labeled with a fluorescently conjugated monoclonal antibody (clone 16C2) directed against the serine 239 phosphorylated form of VASP and, as a platelet identifier, CD61. Analysis was performed in a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA). The platelet reactivity index (PRI) was calculated after subtracting background fluorescence, according to the manufacturer's recommendations using the formula PRI = [(MFI (PGE1) −MFI (PGE1+ADP)) /MFI (PGE1) ]×100, where MFI is the mean fluorescence intensity.
HEPES-saline buffer was added as a control (i.e. no antagonist, 0% inhibition). The possible agonist property of Ap 4 A on P2Y 12 was tested by adding Ap 4 A to the tube incubated with PGE 1 in the absence of ADP.
To evaluate degradation and the possibility of generating biologically active metabolites of Ap 4 A in the VASP assay, Ap 4 A was incubated with whole blood and the PGE 1 reagent from the VASP kit for 0, 3, 6 and 10 minutes. The mixture was centrifuged at 13,600 g for 1 minute and the supernatant retrieved and stored at −80°C until analysis. Prior to analysis by high performance liquid chromatography (HPLC), proteins were removed by perchloric acid precipitation and the samples centrifuged (13,000 g) and filtered (0.45 µ nylon).
P2Y 1 -mediated cytosolic calcium increase measured by flow cytometry with the calcium indicator FLUO-4
The ADP-dependent, P2Y 1 -mediated increase in platelet cytosolic calcium was measured by detecting changes in FLUO-4 fluorescence ( Fig. 1) , as previously described [24] . In brief, one part of citrated whole blood was added to 9 parts of a loading solution consisting of FLUO-4 (5 µM final concentration), CD41-PE-Cy5 P2X 1 receptors are ligand-gated ion channels which, when triggered, cause cytosolic Ca 2+ to increase by allowing entry of extracellular Ca 2+ (Fig. 1) . Measurement of P2X 1 -mediated entry of extracellular Ca 2+ with FLUO-4 differed from measurement of P2Y 1 -mediated increase in cytosolic Ca 2+ from intracellular stores in that 1) blood was collected in PPACK (0.3 mM) rather than sodium citrate, to preserve physiologic extracellular Ca 2+ levels, 2) apyrase (1.8 µM final concentration) was added immediately upon blood collection to degrade any ATP present, thereby avoiding P2X 1 receptor desensitization. [1, 25] , 3) prior to loading platelets with FLUO-4, PRP was separated from erythrocytes in order to minimize erythrocyte-derived nucleotides, and 4) FLUO-4-loaded platelets were diluted and analyzed in buffer containing Ca 2+ (2 mM) rather than in Ca 2+ -free buffer to provide physiologic levels of extracellular Ca 2+ . Platelets in apyrase-treated, PPACK-anticoagulated PRP were loaded with FLUO-4 for 30 minutes in the presence of probenecid (1 mM), diluted in HEPES-saline buffer containing 2 mM CaCl 2 , and then baseline FLUO-4 fluorescence was obtained. P2X 1 -dependent entry of extracellular Ca 2+ was demonstrated by increased FLUO-4 fluorescence upon addition of the specific P2X 1 receptor agonist β,γ-CH 2 -ATP (20 µM), and the absence of this increase when platelets were resuspended in 1 mM EGTA, HEPES-saline buffer, or prepared without addition of apyrase to preserve P2X 1 activity. FLUO-4 fluorescence after addition of various concentrations of Ap 4 A to this system was used to evaluate agonist activity on P2X 1 . In addition, the ability of Ap 4 A (50 µM) to block P2X 1 activation by β,γ-CH 2 -ATP (20 µM) was tested. To ensure that the increase of cytosolic Ca 2+ in these experiments was not due to spurious P2Y 1 -mediated Ca 2+ increase, some experiments were done in the presence of 1 mM EGTA in HEPES-saline buffer, MRS2179 (100 µM, a P2Y 1 receptor antagonist), [26, 27] or both.
Statistical analysis
The results were analyzed by GraphPad Prism software, version 4.00 for Windows (GraphPad Software, San Diego, CA). All results are expressed as mean ± standard error of the mean (SEM). Student's t-test was used to determine statistical significance when two groups of data were compared. One way ANOVA and Bonferroni's multiple comparison test were used when three or more groups of data were compared.
Results
Inhibition of ADP-induced platelet aggregation
Ap 4 A inhibited maximal ADP-induced platelet aggregation and, at a high concentration (100 µM), prevented secondary aggregation and resulted in disaggregation ( Fig. 2A) . Dosedependent inhibition of ADP-induced platelet aggregation determined by the 96-well microplate method is shown in Fig. 2B . The IC 50 was 9.8 ± 2.8 µM.
Agonist and antagonist properties of Ap 4 A on P2Y 12 receptors
The unstimulated baseline VASP phosphorylation MFI was obtained by treating platelets with PGE1 in all experiments (Fig. 3) . As expected, the addition of 3 µM ADP reduced VASP phosphorylation (Fig. 3, open bar) . Ap 4 A was added to attenuate this ADP effect as a potential antagonist (in comparison with PGE 1 +ADP) or to reduce VASP phosphorylation by itself as a potential agonist (in comparison with PGE 1 alone). VASP phosphorylation in the presence of 15.6 µM Ap 4 A (Fig. 3 , hash-marked grey bar) was significantly reduced compared to that obtained with PGE 1 alone (Fig. 3, grey In the presence of increasing concentrations of Ap 4 A, there was a dose-dependent blockade of ADP's effect, resulting in higher levels of phosphorylated VASP (Fig. 3, hash-marked open  bars) . The calculated PRI for the inhibition of VASP phosphorylation induced by ADP relative to the maximal VASP phosphorylation without ADP was 89.5 ± 2.1%, 74.7 ± 1.0%, 61.5 ± 9.4%, and 48.9 ± 6.2% for 0, 15.6, 62.5, and 250 µM Ap 4 A, respectively. Thus, the IC 50 for Ap 4 A inhibition of the ADP-induced, P2Y 12 -mediated response was >250 µM.
Agonist and antagonist properties of Ap 4 A on P2Y 1 receptors
ADP stimulation of P2Y 1 results in platelet shape change which can be measured by the change in transmittance in an aggregometer. Ap 4 A inhibited 3 µM ADP-induced platelet shape change in a dose-dependent manner (Fig. 4A, estimated IC 50 200 µM) . ADP stimulation of P2Y 1 also results in increases in cytosolic Ca 2+ (Fig. 1) . Therefore, we evaluated the effect of Ap 4 A on the ADP-induced increase in cytoplasmic Ca 2+ . In platelets prepared in the absence of apyrase, i.e. without preserving the activity of P2X 1 , and without addition of extracellular Ca 2+ , 3 µM ADP produced an approximately 3.5-fold increase in FLUO-4 fluorescence and this increase was inhibited by Ap 4 A in a dose-dependent manner (Fig. 4B) , with an IC 50 of 40.8 ± 12.3 µM. That a higher concentration of Ap 4 A was required for 50% inhibition ADP-stimulated platelet shape change (~200 µM) than was required for inhibition of ADP-stimulated increase in cytoplasmic Ca 2+ from intracellular stores (~40 µM) is not surprising since platelet shape change is likely triggered by a low threshold increase in cytoplasmic Ca 2+ , and thus would require an amount of Ap 4 A that reduces the cytoplasmic Ca 2+ increase by greater than 50%. Thus, as evidenced by two independent assays, platelet shape change and increase in cytosolic Ca 2+ , Ap 4 A is an antagonist of P2Y 1 receptors.
Under the same conditions, but in the absence of ADP, Ap 4 A at concentrations up to 250 µM did not induce an increase in cytoplasmic Ca +2 as measured by the FLUO-4 fluorescence ratio in comparison with HEPES-saline vehicle control (1.18 ± 0.09 vs. 1.09 ± 0.06, mean ± SEM, n = 5, p = 0.161). Thus, Ap 4 A is not an agonist of P2Y 1 .
Agonist and antagonist properties of Ap 4 A on P2X 1 receptors
Platelet P2X 1 function was not a factor in the platelet aggregation, shape change, P2Y 1 release of internal Ca 2+ , and P2Y 12 -mediated VASP assays described above since activity of P2X 1 was not preserved under the conditions used to isolate platelets for those assays. However, when platelets were prepared using protocols to protect P2X 1 from desensitization and suspended in buffer containing 2 mM Ca 2+ , Ap 4 A at 0.1 µM and higher concentrations induced an increase in platelet intracellular Ca 2+ (Fig. 5A) . For Ap 4 A concentrations between 0.1 and 10 µM, this increase was entirely due to the P2X 1 -mediated entry of extracellular Ca 2+ , because it was eliminated when platelets were resuspended in buffer containing EGTA instead of Ca 2+ (Fig. 5) . Moreover, failure of the P2Y 1 antagonist MRS2179 at 100 µM to inhibit the Ap 4 A-stimulated rise in Ca 2+ (Fig. 5A ) indicated that this rise was not due to direct or indirect stimulation of P2Y 1 . Similarly, the majority of the cytoplasmic Ca 2+ rise produced by 50 µM Ap 4 A was eliminated in the presence of EGTA and could not be blocked by MRS2179. However, there was a small, but statistically significant component of the Ca 2+ increase at 50 µM Ap 4 A that was not blocked by EGTA but was blocked by MRS2179, indicating some P2Y 1 -mediated contribution at this high Ap 4 A concentration. The biphasic dose-response observed for Ap 4 A (Fig. 5A ) was also observed with the specific P2X 1 receptor agonist β,γ-CH 2 -ATP (data not shown). Finally, MRS2159, a selective P2X 1 antagonist [28] , added in parallel with Ap 4 A, dose-dependently blocked Ap 4 A-stimulated Ca 2+ entry into platelets (Fig.  6) , demonstrating that the Ap 4 A-induced rise in platelet cytoplasmic Ca 2+ requires P2X 1 . Taken together, these data show that Ap 4 A is an agonist of platelet P2X 1 receptors.
When 50 µM Ap 4 A was added to a submaximal concentration of a selective P2X 1 agonist, 20 µM β,γ-CH 2 -ATP, the post-stimulation FLUO-4 MFI was higher than with 20 µM β,γ-CH 2 -ATP alone (4.43 ± 0.20 vs. 3.57 ± 0.47, p = 0.034, n = 3). Thus, there was no evidence that Ap 4 A is a P2X 1 antagonist, and the enhanced response suggested that Ap 4 A augmented the P2X 1 agonist effect of 20 µM β,γ-CH 2 -ATP.
Discussion
The major findings of this study are that Ap 4 A, a known constituent of platelet dense granules, is: a) an antagonist of platelet P2Y 1 and P2Y 12 receptors, where it inhibits the effects of the agonist ADP, b) an agonist of P2X 1 receptors, and c) a partial agonist of P2Y 12 receptors. These stimulating and inhibiting activities are summarized in Table 1 .
Antagonist effects of Ap 4 A on platelet P2Y 1 and P2Y 12 receptors
Previously published studies showed that Ap 4 A and its analogs inhibit ADP-induced platelet aggregation and several aspects of platelet activation including release action, cytoplasmic calcium mobilization, thromboxane production, fibrinogen binding, and platelet factor 3 activities [14] . This inhibition of platelet functions was considered to be mediated through the P 2T pathway [14] , a poorly defined term used before the currently known purinergic receptors, P2X 1 , P2Y 1 and P2Y 12 , were cloned and their functions well characterized. In the current study, consistent with these previous reports [14] , we found that Ap 4 A inhibits 3 µM ADPinduced platelet aggregation. The platelet disaggregation that was observed with 100 µM Ap 4 A (Fig. 2) suggests that Ap 4 A inhibited the P2Y 12 pathway. On the other hand, we also found that Ap 4 A inhibits 3 µM ADP-induced platelet shape change (Fig. 4A) , which is mainly mediated by P2Y 1 [1, 25] .
ADP-induced platelet signaling through P2Y 1 and P2Y 12 receptors can be examined by specific assays, i.e. ADP-induced calcium increase for P2Y 1 receptors and ADP-induced VASP phosphorylation decrease for P2Y 12 receptors (Fig. 1) . In the present study, 3 µM ADPinduced platelet cytosolic Ca 2+ rise was inhibited by Ap 4 A with an IC 50 of 40.8 µM (Fig. 4B) . This result confirmed that Ap 4 A is a P2Y 1 antagonist. In addition, the decrease in ADP-induced VASP phosphorylation was inhibited by Ap 4 A in a dose-dependent manner (Fig. 3) . While Ap 4 A inhibition of ADP-stimulated, P2Y 1 -mediated increase in cytosolic calcium was measured within seconds of adding Ap 4 A and ADP to cells, the P2Y 12 mediated VASP response was measured 10 minutes after adding Ap 4 A to whole blood, raising the possibility that metabolites of Ap 4 A, and not Ap 4 A per se may be responsible for effects on P2Y 12 .
However, this appears unlikely since HPLC analysis showed no breakdown of Ap 4 A when incubated under VASP assay conditions. Taken together, these results indicate that Ap 4 A is an antagonist for both P2Y 1 and P2Y 12 receptors. Such dual specificity on platelet P2Y 1 and P2Y 12 receptors has been recently reported for other compounds [29, 30] . Although 3 µM ADP was used as the stimulant in all experiments, the IC 50 for inhibition of platelet aggregation (9.8 ± 2.8 µM) was 4-fold lower than the IC 50 for the inhibition of the P2Y 1 -mediated increase of cytosolic Ca 2+ (40.8 ± 12.3 µM) and more than 25-fold lower than the IC 50 for the P2Y 12 -mediated decrease in VASP phosphorylation (>250 µM). Our results are similar to the findings of Cattaneo et al. [29] who reported that both MRS2298 and MRS2496 inhibited ADP-induced platelet aggregation, shape change and P2Y 1 -mediated Ca 2+ increase but, at higher concentrations, these compounds also partially inhibited ADPinduced decrease of cAMP, possibly via the P2Y 12 pathway. Furthermore, Cattaneo et al. [29] reported that the IC 50 s of MRS2298 and MRS2496 for inhibition of platelet aggregation were lower than those for cytosolic Ca 2+ increase and shape change. These data suggest synergism between P2Y 1 and P2Y 12 antagonism. Indeed, the synergism of antagonism between P2Y 1 and P2Y 12 receptors using selective antagonists for each receptor has been well documented in vitro [31] . The present findings and those of Cattaneo et al. [29] demonstrate that synergism of inhibition may occur for a single compound with dual receptor antagonist properties. However, the present findings are the first report of an endogenous molecule released by platelets that has a dual and synergistic inhibitory effect on both P2Y 1 and P2Y 12 receptors. This synergism may be explained, at least in part, by the recently reported reciprocal cross-talk between P2Y 1 and P2Y 12 receptors [32, 33] .
Agonist effects of Ap 4 A on platelet P2Y 12 but not P2Y 1 receptors
In addition to the inhibitory effects of Ap 4 A on P2Y 1 and P2Y 12 pathways, we demonstrated that Ap 4 A attenuated PGE1-stimulated VASP phosphorylation (Fig. 3) . This attenuation was prevented by AR-C69931, demonstrating specificity for P2Y 12 . These data indicates that Ap 4 A either directly or indirectly (e.g., via metabolites) results in platelet P2Y 12 activation. However, our study of metabolites after incubation with whole blood suggests such effects result directly from Ap 4 A rather than its metabolites.
The apparently opposing effects of Ap 4 A, as a weak agonist of P2Y 12 , causing a decrease in VASP phosphorylation, and at the same time as a partial antagonist of P2Y 12 Although Ap 4 A and other diadenosine polyphosphates have been reported to activate P2Y 1 receptors in other cell types [34, 35] , their agonist activity on platelet P2Y 1 receptors is unknown. We found that Ap 4 A stimulation did not result in P2Y 1 -mediated increase of platelet cytosolic Ca 2+ and, therefore, does not act as a platelet P2Y 1 receptor agonist.
Agonist effects of Ap 4 A on platelet P2X 1 receptors
It is well known that Ap 4 A is an agonist for P2X receptors in rat vas deferens and human urinary bladders [17, 36] . In platelets, Sage et al. [4] showed that Ap 4 A may induce a rise in cytosolic Ca 2+ and suggested that this was mediated by P2X 1 . Such an Ap 4 A-induced platelet cytosolic Ca 2+ rise was also observed in our study with extracellular Ca 2+ available, but was obliterated when extracellular Ca 2+ was removed by the chelating agent EGTA (Fig. 5A) . These data confirm that the cytosolic Ca 2+ increase resulted solely from an influx of extracellular Ca 2+ , i.e. a P2X-mediated effect (Fig. 1) . Moreover, MRS2159, a selective P2X 1 antagonist [28] , blocked the Ap 4 A-induced influx of extracellular Ca 2+ , demonstrating Ap 4 A is a platelet P2X 1 agonist. Although Ap 4 A and other adenosine polyphosphates can be both agonists and antagonists of P2Y 1 and P2Y 12 receptors, the present study has demonstrated that Ap 4 A functions only as an agonist, not an antagonist, for platelet P2X 1 receptors.
Possible pathophysiologic roles of Ap 4 A
The plasma concentration of Ap 4 A has been reported to range from 0.33 − 1.0 µM [8, 10, 13] . However, in the platelet-rich microenvironment where a thrombus is formed or high shear force is generated by vessel damage, the local concentration of Ap 4 A may reach up to 100 µM as a result of dense granule release by involved platelets [8, 10, 13] . The present study has demonstrated that 0.1-1 µM Ap 4 A has significant agonist effects on platelet P2X 1 receptors. In addition, Ap 4 A inhibits ADP-induced aggregation and cytosolic Ca 2+ increase with IC 50 s of 9.8 ± 2.8 and 40.8 ± 12.3 µM, respectively. Although the concentrations of Ap 4 A required to antagonize ADP effects on platelet P2Y 1 and P2Y 12 receptors are high compared to ADP, it is well known that Ap 4 A and other diadenosine polyphosphates are more stable than ADP and ATP [10] . Whereas ADP is rapidly inactivated by ecto-nucleotidase [37] , Ap 4 A is more resistant to hydrolysis [10] and therefore attains higher concentrations than ADP in plasma and in the local thrombotic microenvironment. Whether this high concentration can be reached in any pathophysiological conditions is unclear therefore the pathophysiologic role of high concentration Ap 4 A is speculative.
Pharmacologic Perspectives
Ap 4 A is the backbone of some chemical derivatives being developed as potential antiplatelet agents. In vitro antiplatelet [14, 38] and in vivo antithrombotic effects [39, 40] of Ap 4 A and its derivatives have been reported, and antithrombotic potency is improved after certain chemical structure modifications [14, 38] . The current study shows that Ap 4 A has antagonist effects for platelet P2Y 12 receptors, the target of several effective antithrombotic agents including clopidogrel and prasugrel [41] . Ap 4 A derivatives, while different in potencies and selectivity towards platelet receptors (results to be published), may have antiplatelet effects comparable to clinically available drugs such as clopidogrel. In clinical studies [5] , standard doses of the widely-used, FDA-approved P2Y 12 antagonist clopidogrel reduced VASP PRI to 61.1 ± 17% mean ± SD) of maximal. In the present study, 62.5 µM Ap 4 A resulted in a similar reduction of VASP PRI, to 61.5 ± 9.4%. Thus, Ap 4 A released as a result of initial platelet activation may block subsequent activation of platelets to the same degree as pharmacological doses of clopidogrel. Furthermore, in the present study 250 µM Ap 4 A reduced VASP PRI to 48.9 ± 6.2%.
The potential advantage of Ap 4 A and its derivatives as therapeutic antiplatelet agents is that, unlike clopidogrel, prasugrel, or other P2Y 12 antagonist in development, they also have, as demonstrated in the present study, a synergistic inhibitory effect on platelet P2Y 1 receptors. One potential concern of using Ap 4 A or its derivatives as antithrombotic agents might be their action on platelet P2X 1 receptors. Recent studies indicate that P2X 1 has an important role in platelet activation, particularly under conditions of shear stress [19] . Nevertheless, the present study on the mechanism of platelet inhibition by Ap 4 A provides a framework for future development of Ap 4 A-derived antiplatelet agents. Chemically modified Ap 4 A derivatives may be compared to Ap 4 A for their selective potency on platelet purinergic receptors. The ligand is ADP for P2Y 1 and P2Y 12 , and ATP for P2X 1 . P2X 1 is a ligand-gated ion channel which allows extracellular Ca 2+ to shift into the cytoplasm upon activation. ADP binding to the P2Y 1 receptor induces activation of phospholipase C β (PLC-β), which, via inositol triphosphate (IP 3 ), subsequently leads to release of cytoplasmic Ca 2+ pools. Both P2X 1 and P2Y 1 activation cause cytosolic Ca 2+ increase, which in the present study was measured by flow cytometry with the Ca 2+ indicator, FLUO-4. ADP binding to platelet P2Y 12 receptors results in a decrease of cytoplasmic cAMP by inhibiting adenylyl cyclase. cAMP subsequently leads, via protein kinase A (PKA), to phosphorylation of vasodilator stimulated phosphoprotein (VASP), which was measured by flow cytometry. 
